BLA Submitted to FDA for PET Imaging Agent TLX250-CDx in RCC

A biologics license application seeking the approval of the investigational positron emission tomography imaging agent 89Zr-DFO-girentuximab in clear cell renal cell carcinoma has been submitted to the FDA.

Related Keywords

Cdx Zircaix , Brian Shuch , James Stonecypher , Alvin Carrie Meinhardt , Christian Behrenbruch , Institute Of Urologic Oncology , Telix Group , Kidney Cancer Program , Kidney Cancer Research , Cancers Symposium , Carrie Meinhardt Endowed Chair , Urologic Oncology , Bernhardj C , News , Genitourinary Cancers , Gu Cancer , Nrcc , Renal Cell Carcinoma , Kidney Cancer , Clear Cell Renal Carcinoma , Fda ,